Company intelligence / Profile preview

GenomeMe

Richmond, British Columbia, Canadagenomeme.ca ↗

Ownership: Private
Employees: ~6
Development stage: Commercial

Overview

GenomeMe has developed over 260 clinical IHC antibodies in-house for diagnostic use, with several receiving top "Optimal" ratings in NordiQC test schemes[1][2]

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mouse and rabbit IHC antibodies)
Industry: Pathology

Partnerships

Distributors including Attogene (USA), 2BScientific, Sobek Bio

Beyond the preview

Go deeper on GenomeMe.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GenomeMe.

Explore the full profile